Zhuzhou Qianjin Pharmaceutical (600479.SH) subsidiary obtained the drug registration certificate for lactulose oral solution.
Qianjin Pharmaceutical Industry (600479.SH) issued an announcement. Recently, its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (referred to as "Qianjin Xiangjiang Pharmaceutical"), has received the drug registration certificate for lactulose oral solution approved and issued by the National Medical Products Administration.
Zhuzhou Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. ("Qianjin Xiangjiang Pharmaceutical"), has recently received the Drug Registration Certificate for Lactulose Oral Solution issued by the National Medical Products Administration.
Lactulose Oral Solution is used for chronic or habitual constipation: regulating the physiological rhythm of the colon; hepatic encephalopathy: used to treat and prevent hepatic coma or pre-coma state. The approval of the Drug Registration Certificate for Lactulose Oral Solution further enriches the company's product pipeline, which is beneficial for the company's sustainable development.
Related Articles
Hunan Gold Corporation (002155.SZ): Xilong Mining Headquarters Resumes Production.
Uber Technologies, Inc. (UBER.US) faces obstacles in its acquisition! Delivery Hero rejects the offer, causing the stock price to soar 10% and surpass the bid.
Contec Medical Systems (300869.SZ) subsidiary products have obtained EU MDR certification.
Hunan Gold Corporation (002155.SZ): Xilong Mining Headquarters Resumes Production.
Uber Technologies, Inc. (UBER.US) faces obstacles in its acquisition! Delivery Hero rejects the offer, causing the stock price to soar 10% and surpass the bid.
Contec Medical Systems (300869.SZ) subsidiary products have obtained EU MDR certification.
